BioScrip reports revenue growth

Thursday, May 2, 2019

DENVER – BioScrip reported revenues of $179 million for the first quarter of 2019, an increase of 6.2% over the first quarter of 2018. Net loss from continuing operations was $10.3 million vs. $13 million. Adjusted EBITDA was $7.1 million, up 25.6%, despite a bad debt expense increase of $4.5 million. “This is the third consecutive quarter of comparable net revenue growth for BioScrip, and we are confident this trend will continue,” said Daniel Greenleaf, president and CEO. BioScrip’s merger with Option Care, announced in March, is proceeding as planned, Greenleaf said. “We remain incredibly enthusiastic about the strategic and financial virtues of this combination,” he said.